• Monash IVF received a revised, unsolicited, conditional and non-binding indicative proposal from a consortium
• The Board unanimously determined that the proposal undervalues Monash IVF and is not in the best interest of shareholders
• The Board is supportive of the new CEO's strategy to return stability and growth to Monash IVF

Monash IVF Group Limited (ASX: MVF) has received a revised, unsolicited, conditional and non-binding indicative proposal from a consortium comprising Genesis Capital Investment Management Pty Ltd and WHSP Holdings Pty Limited to acquire 100% of the shares in Monash IVF by way of a Scheme of Arrangement at $0.90 per share. After considering the proposal with the assistance of its financial and legal advisers, the Monash IVF Board has unanimously determined that the proposal undervalues the company and is not in the best interest of the company's shareholders as a whole. Factors considered by the Board in forming its decision included the offer price being at a substantial discount to comparable IVF transactions in the Australian market, as well as the Board's support for the newly appointed CEO, Dr Victoria Atkinson, and her strategy to return stability and growth to Monash IVF. The Board remains open to discussions regarding a change of control transaction at a higher valuation, but will only progress such a proposal if it believes it represents compelling value for Monash IVF shareholders.